Mitchell, M.M., Mendelson, J.E., Gryczynski, J., Carswell, S.B., & Schwartz, R.P., Exploring trends in breathalyzer test results among participants of the Ria Treatment Program using dynamic structural equation modeling, CPDD 80th Annual Scientific Meeting, San Diego, California 2018. Patients in the Ria program reduced their drinking by an average of 57% in six months.
Mendelson, J.E., Nix, R.P., Deacon, D., Xu, S., Engaging Patients in AUD Treatment with Technology, Submitted for publication. 57% of patients who started the Ria program remained in the program at 6 months, 4X better than medical management with oral Naltrexone.
Kranzler H.R., Stephenson J.J., Montejano L., Wang S., Gastfriend D.R., Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization, Addiction. 2008 Nov;103(11):1801-8. Only 14% of patients persist with oral Naltrexone for 6-months.